US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
GB9718913D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
DE19802377A1
(de)
*
|
1998-01-22 |
1999-08-19 |
Max Planck Gesellschaft |
Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
|
EP1066257A2
(de)
*
|
1998-03-26 |
2001-01-10 |
Sugen, Inc. |
Heterozyklische stoffklassen für die modulation der tyrosine protein kinase
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
CA2314156C
(en)
*
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
TR200101858T2
(tr)
*
|
1998-12-17 |
2001-12-21 |
F.Hoffmann-La Roche Ag |
JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
|
AU770060B2
(en)
*
|
1998-12-17 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
4,5-azolo-oxindoles
|
TR200101860T2
(tr)
|
1998-12-17 |
2001-12-21 |
F.Hoffmann-La Roche Ag |
Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
BR9916272A
(pt)
*
|
1998-12-17 |
2001-09-04 |
Hoffmann La Roche |
4 e 5-alquiniloxindóis e 4 e 5-alqueniloxindóis
|
KR20010108024A
(ko)
|
1998-12-17 |
2001-12-07 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
단백질 키나제 억제제로서의 4,5-피라진옥신돌
|
GB9904930D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Thiazoloindolinone compounds
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
GB9904995D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Substituted aza-oxindole derivatives
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
CA2368041A1
(en)
*
|
1999-03-24 |
2000-09-28 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
WO2001037820A2
(en)
*
|
1999-11-24 |
2001-05-31 |
Sugen, Inc. |
Ionizable indolinone derivatives and their use as ptk ligands
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
ES2383763T3
(es)
*
|
1999-12-22 |
2012-06-26 |
The Scripps Research Institute |
Composiciones farmacéuticas que comprenden Src y/o Yes y su utilización
|
DE60029138T2
(de)
*
|
1999-12-22 |
2007-06-06 |
Sugen, Inc., San Francisco |
Verwendung von Indolinonverbindungen zur Herstellung von Pharmazeutika für die Modulation der Funktion c-kit Proteintyrosinkinase
|
SI1255752T1
(sl)
*
|
2000-02-15 |
2007-12-31 |
Pharmacia & Upjohn Co Llc |
S pirolom substituirani zaviralci 2-indolinon protein kinaza
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
TWI270545B
(en)
|
2000-05-24 |
2007-01-11 |
Sugen Inc |
Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
JP2003535847A
(ja)
|
2000-06-02 |
2003-12-02 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ/ホスファターゼ阻害剤としてのインドリノン誘導体
|
US6635640B2
(en)
|
2000-06-30 |
2003-10-21 |
Sugen, Inc. |
4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
CA2417500C
(en)
*
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
PE20020776A1
(es)
|
2000-12-20 |
2002-08-22 |
Sugen Inc |
Indolinonas 4-aril sustituidas
|
ATE464322T1
(de)
|
2001-01-05 |
2010-04-15 |
Pfizer |
Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
|
US6504034B2
(en)
|
2001-01-23 |
2003-01-07 |
Hoffmann-La Roche Inc. |
Naphthostyrils
|
FR2821358B1
(fr)
*
|
2001-02-27 |
2006-04-07 |
Aventis Pharma Sa |
Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique
|
US7186745B2
(en)
|
2001-03-06 |
2007-03-06 |
Astrazeneca Ab |
Indolone derivatives having vascular damaging activity
|
US6599902B2
(en)
|
2001-05-30 |
2003-07-29 |
Sugen, Inc. |
5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
WO2003000251A1
(en)
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel idolinones and uses thereof
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
WO2003002106A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
EP1434991B1
(de)
|
2001-06-29 |
2007-10-17 |
AB Science |
C-kit inhibitoren
|
CA2452366A1
(en)
*
|
2001-06-29 |
2003-01-16 |
Ab Science |
Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
|
EP1401415B1
(de)
|
2001-06-29 |
2006-06-21 |
AB Science |
Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
|
WO2003002105A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating bone loss
|
ATE343415T1
(de)
|
2001-06-29 |
2006-11-15 |
Ab Science |
Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
|
DE10134196B4
(de)
*
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
US6777417B2
(en)
|
2001-09-10 |
2004-08-17 |
Sugen, Inc. |
3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
ATE349210T1
(de)
|
2002-07-09 |
2007-01-15 |
Boehringer Ingelheim Pharma |
Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
|
JP4335136B2
(ja)
*
|
2002-08-09 |
2009-09-30 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害薬
|
EP1534695B1
(de)
*
|
2002-08-09 |
2010-09-29 |
Merck Sharp & Dohme Corp. |
Tyrosinkinaseinhibitoren
|
WO2004050681A2
(en)
*
|
2002-11-15 |
2004-06-17 |
Exelixis, Inc. |
Kinase modulators
|
OA12977A
(en)
|
2002-12-19 |
2006-10-13 |
Pfizer |
2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthamic diseases.
|
US7781464B2
(en)
*
|
2003-01-17 |
2010-08-24 |
Bexel Pharmaceuticals, Inc. |
Heterocyclic diphenyl ethers
|
GB0302512D0
(en)
*
|
2003-02-03 |
2003-03-05 |
Arrow Therapeutics Ltd |
Compounds
|
PL216368B1
(pl)
|
2003-02-26 |
2014-03-31 |
Sugen |
Związki aminoheteroarylowe oraz ich zastosowanie
|
TWI369353B
(en)
|
2003-03-07 |
2012-08-01 |
Santen Pharmaceutical Co Ltd |
Novel compound having 4-pyridylalkylthio group as substituent
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
NZ547009A
(en)
|
2003-12-23 |
2009-09-25 |
Pfizer |
Novel quinoline derivatives
|
WO2005085201A1
(ja)
|
2004-02-17 |
2005-09-15 |
Santen Pharmaceutical Co., Ltd. |
置換又は無置換アミノ基を導入した4-ピリジルアルキルチオ基を有する新規環式化合物
|
PE20060430A1
(es)
|
2004-06-09 |
2006-05-25 |
Glaxo Group Ltd |
Derivados de pirrolopiridina como moduladores de los receptores cannabinoides
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
PT1786785E
(pt)
|
2004-08-26 |
2010-05-21 |
Pfizer |
Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
WO2006071035A1
(en)
*
|
2004-12-31 |
2006-07-06 |
Lg Life Sciences, Ltd. |
Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
|
US7759383B2
(en)
|
2005-02-22 |
2010-07-20 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of MDM2 and the uses thereof
|
DE602006016564D1
(de)
*
|
2005-03-03 |
2010-10-14 |
Santen Pharmaceutical Co Ltd |
Neue cyclische verbindung mit chinolylalkylthiogruppe
|
EP1861715B1
(de)
|
2005-03-16 |
2010-08-11 |
OSI Pharmaceuticals, Inc. |
Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
|
EP1863848A4
(de)
|
2005-03-31 |
2009-09-23 |
Agensys Inc |
An 161p2f10b-proteine bindende antikörper und verwandte moleküle
|
US7906511B2
(en)
|
2005-03-31 |
2011-03-15 |
Santen Pharmaceutical Co., Ltd. |
Cyclic compound having pyrimidinylalkylthio group
|
UA95775C2
(uk)
|
2005-04-26 |
2011-09-12 |
Пфайзер Инк. |
Антитіло, яке специфічно зв'язується з р-кадгерином
|
KR101536506B1
(ko)
|
2005-09-07 |
2015-07-14 |
암젠 프레몬트 인코포레이티드 |
액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
|
JP5055284B2
(ja)
|
2005-09-20 |
2012-10-24 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
|
US7855225B2
(en)
|
2006-03-02 |
2010-12-21 |
Astellas Pharma Inc. |
17βHSD type 5 inhibitor
|
KR20090014258A
(ko)
*
|
2006-06-01 |
2009-02-09 |
바스프 에스이 |
치환된 비페닐의 제조 방법
|
US8063034B2
(en)
|
2007-01-29 |
2011-11-22 |
Santen Pharmaceutical Co., Ltd. |
Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
|
EP1992344A1
(de)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
WO2010090764A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2011008696A2
(en)
|
2009-07-13 |
2011-01-20 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011014726A1
(en)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
RU2012114094A
(ru)
|
2009-09-11 |
2013-10-20 |
Дженентек, Инк. |
Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
CN102666485A
(zh)
*
|
2009-09-21 |
2012-09-12 |
霍夫曼-拉罗奇有限公司 |
烯烃羟吲哚衍生物及其用于治疗肥胖症,糖尿病和高脂血症的应用
|
WO2011032320A1
(en)
*
|
2009-09-21 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Novel alkene oxindole derivatives
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
LT3150610T
(lt)
|
2010-02-12 |
2019-11-11 |
Pfizer |
8-fluor-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ono druskos ir polimorfai
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
CN103068851B
(zh)
|
2010-06-16 |
2015-03-11 |
高等教育联邦***-匹兹堡大学 |
内质蛋白的抗体及其用途
|
CN104569395A
(zh)
|
2010-07-19 |
2015-04-29 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
KR20130091745A
(ko)
|
2010-07-19 |
2013-08-19 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
JP5802756B2
(ja)
|
2010-10-20 |
2015-11-04 |
ファイザー・インク |
スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
US20140178368A1
(en)
|
2011-04-19 |
2014-06-26 |
Leslie Lynne SHARP |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
CN102268000A
(zh)
*
|
2011-05-05 |
2011-12-07 |
温州医学院 |
一类新型螺杂环化合物及其作为治疗剂的用途
|
WO2012178015A2
(en)
*
|
2011-06-24 |
2012-12-27 |
Zenobia Therapeutics, Inc. |
Lrrk2 inhibitors
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
PE20141228A1
(es)
|
2011-09-22 |
2014-10-01 |
Pfizer |
Derivados de pirrolopirimidina y purina
|
WO2013050725A1
(en)
|
2011-10-04 |
2013-04-11 |
King's College London |
Ige anti -hmw-maa antibody
|
WO2013068902A1
(en)
|
2011-11-08 |
2013-05-16 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-m-csf antibodies
|
CN103183665B
(zh)
*
|
2011-12-30 |
2015-10-14 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
具有酪氨酸激酶抑制活性的物质、其制备方法及用途
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN102718659B
(zh)
*
|
2012-06-27 |
2014-12-17 |
东南大学 |
一种4-溴-2-硝基苯乙酸的合成方法
|
US9394257B2
(en)
|
2012-10-16 |
2016-07-19 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for their use
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
EP2970205B1
(de)
|
2013-03-14 |
2019-05-08 |
Tolero Pharmaceuticals, Inc. |
Jak2- und alk2-inhibitoren und verfahren zu deren verwendung
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
JP6946000B2
(ja)
|
2013-10-04 |
2021-10-06 |
アプトース バイオサイエンシーズ, インコーポレイテッド |
がんの治療用組成物及び方法
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN106536753B
(zh)
|
2014-04-04 |
2020-07-21 |
中美冠科生物技术(太仓)有限公司 |
用于确定对mek/erk抑制剂的应答性的方法
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
CA2947130C
(en)
|
2014-04-30 |
2018-10-02 |
Pfizer Inc. |
Cycloalkyl-linked diheterocycle derivatives
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
CN106999578B
(zh)
|
2014-07-31 |
2022-03-04 |
美国政府(由卫生和人类服务部的部长所代表) |
针对epha4的人类单克隆抗体和其用途
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
CA2982928A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
CN107709344B
(zh)
|
2015-05-01 |
2022-07-15 |
共晶制药股份有限公司 |
用于治疗黄病毒科病毒和癌症的核苷类似物
|
EP4086264B1
(de)
|
2015-05-18 |
2023-10-25 |
Sumitomo Pharma Oncology, Inc. |
Alvocidib-prodrugs mit erhöhter bioverfügbarkeit
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
AU2016301315C1
(en)
|
2015-08-03 |
2022-07-07 |
Sumitomo Pharma Oncology, Inc. |
Combination therapies for treatment of cancer
|
KR20180100125A
(ko)
|
2015-12-03 |
2018-09-07 |
아지오스 파마슈티컬스 아이엔씨. |
Mtap 널 암을 치료하기 위한 mat2a 억제제
|
CN105585558A
(zh)
*
|
2015-12-15 |
2016-05-18 |
贵州大学 |
双烷氧基嘧啶拼接3-烯键氧化吲哚衍生物及其制备方法及应用
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
JP2022519923A
(ja)
|
2019-03-22 |
2022-03-25 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
CN115073353A
(zh)
*
|
2021-03-15 |
2022-09-20 |
中国医学科学院药物研究所 |
木脂素类衍生物及其制法和其药物组合物与用途
|
WO2023241620A1
(en)
*
|
2022-06-14 |
2023-12-21 |
Suzhou Keen Therapeutics Co., Ltd. |
Biologically active compounds and methods thereof
|